New hope for tough pancreatic cancer: experimental combo targets Cancer's repair system
NCT ID NCT01489865
Summary
This study tested whether adding a new drug called ABT-888 to standard chemotherapy could better control metastatic pancreatic cancer. The trial enrolled 64 patients whose cancer had spread and who had specific genetic risk factors or family cancer history. ABT-888 works by blocking a protein that helps cancer cells repair themselves, aiming to make the chemotherapy more effective at shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.